Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. betascreen

BETASCREEN

A Unique Pancreatic Human Beta Cells to revolutionize the Diabetes Drug Discovery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 BETASCREEN project word cloud

Explore the words cloud of the BETASCREEN project. It provides you a very rough idea of what is the project "BETASCREEN" about.

company    coherence    commercialization    says    110    predictability    jan    anti    decreasing    screening    pharma    biotech    clinical    disruptive    industry    tornell    surprise    outcome    1billion    big    scarce    quantity    division    million    pharmas    maturity    strategic    faced    tissues    strategy    diabetes    pancreatic    segments    cell    types    portfolio    predictive    europe    accessible    betascreen    ub    turnover    marketed    regulatory    10    pressure    poor    edge    adoption    avenues    first    innovative    industrials    replication    2015    population    overcome    lack    pioneering    exceptional    solution    jobs    ing    technologies    leader    15    drug    commercial    secure    issue    market    generation    samples    biosolutions    beta    revenues    models    line    selling    substitute    industrial    cells    dollars    patients    animal    reproducibility    lines    univercell    think    academia    rate    hope    stem    pharmaceutical    homogeneity    rentability    generating    attrition    astrazeneca    accelerate    90    2021    leaders    world    cutting    human    ultimate    prevents    saving    bottlenecks    creation   

Project "BETASCREEN" data sheet

The following table provides information about the project.

Coordinator		 UNIVERCELL BIOSOLUTIONS SAS 

Organization address
address: PLACE PIERRE POTIER CENTRE PIERRE POTIER CANCEROPOLE ENTREE B
city: TOULOUSE
postcode: 31000
website: www.univercell-biosolutions.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Project website http://www.endocells.com/products-and-services/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-08-01   to  2017-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERCELL BIOSOLUTIONS SAS FR (TOULOUSE) coordinator 50˙000.00

Map

 Project objective

Univercell Biosolutions (UB) is a pioneering biotech company providing unique human cell models to accelerate and secure pharmaceutical products. UB is generating 1 M€ turnover in 2015 selling its first generation of human beta cell lines to 10 world pharma industry leaders. Pharmas rentability is decreasing facing to high regulatory pressure and low clinical predictability on human. The rate of clinical drug failure is about 90% and cost for marketed a new drug reach up to 1billion dollars. Early clinical predictability is a strategic issue for industrials. Jan Tornell an AstraZeneca division leader says: “The big think is that when we get into patients, we want no surprise”. Cells from human tissues samples are scarce and not accessible for Pharmas applications. Thus, Industrials developed substitute from animal with poor clinical predictability. Recently, Stem cell technologies has open new hope in providing large quantity of human cells but is still faced with major bottlenecks: lack of cell maturity (clinical predictability) and low cell population homogeneity (reproducibility) which prevents large adoption by industrials. UB has developed a portfolio of cutting edge technologies to overcome these bottlenecks. The first outcome of BETASCREEN is a disruptive pancreatic beta cell line for anti-diabetes research, with ultimate objective of replication to other cell types. The solution targets pharmaceutical, biotech, and academia. Within BETASCREEN, UB will define best commercialization strategy in coherence with market’s targeted segments and identify industrial partners for large-scale production (Phase 2) and commercialization. BETASCREEN will improve the predictive value of screening by decreasing the drug attrition rate up to 10%. Resulting cost saving for industrials could reach 100 million dollars per innovative new drug development. This will open exceptional commercial avenues for UB with revenues estimated at 15 M€ in 2021 and 110 jobs creation in Europe

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BETASCREEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BETASCREEN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More